WO2012177075A3 - 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물 - Google Patents

항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물 Download PDF

Info

Publication number
WO2012177075A3
WO2012177075A3 PCT/KR2012/004942 KR2012004942W WO2012177075A3 WO 2012177075 A3 WO2012177075 A3 WO 2012177075A3 KR 2012004942 W KR2012004942 W KR 2012004942W WO 2012177075 A3 WO2012177075 A3 WO 2012177075A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bacterial infections
lysophosphatidylcholine
boosting immunity
composition containing
Prior art date
Application number
PCT/KR2012/004942
Other languages
English (en)
French (fr)
Other versions
WO2012177075A2 (ko
Inventor
정재준
구세광
송동근
Original Assignee
주식회사 아리메드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아리메드 filed Critical 주식회사 아리메드
Priority to ES12802590.5T priority Critical patent/ES2655193T3/es
Priority to EP12802590.5A priority patent/EP2740479B1/en
Priority to CN201280040703.6A priority patent/CN103781483B/zh
Priority to JP2014516920A priority patent/JP5953372B2/ja
Priority to US14/128,688 priority patent/US9446061B2/en
Publication of WO2012177075A2 publication Critical patent/WO2012177075A2/ko
Publication of WO2012177075A3 publication Critical patent/WO2012177075A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 라이소포스파티딜콜린 또는 이의 유사체, 및 항생제를 유효성분으로 포함하는 면역 증강 또는 세균성 감염 질환 치료용 약제학적 조성물, 상기 물질을 투여하는 단계를 포함하는 면역 증강 또는 세균성 감염 질환의 치료 방법, 및 상기 물질을 포함하는 면역 증강 또는 세균성 감염 질환의 치료용 키트에 관한 것이다.
PCT/KR2012/004942 2011-06-23 2012-06-22 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물 WO2012177075A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES12802590.5T ES2655193T3 (es) 2011-06-23 2012-06-22 Composición que contiene antibióticos y lisofosfatidilcolina para el estímulo de la inmunidad o el tratamiento de infecciones bacterianas
EP12802590.5A EP2740479B1 (en) 2011-06-23 2012-06-22 Composition containing antibiotics and lysophosphatidylcholine for boosting immunity or treatment of bacterial infections
CN201280040703.6A CN103781483B (zh) 2011-06-23 2012-06-22 包含抗生素及溶血磷脂酰胆碱的免疫增强或细菌性感染疾病治疗用组合物
JP2014516920A JP5953372B2 (ja) 2011-06-23 2012-06-22 抗生剤及びリゾホスファチジルコリンを含む免疫増強または細菌性感染疾患治療用の組成物
US14/128,688 US9446061B2 (en) 2011-06-23 2012-06-22 Composition containing antibiotics and lysophosphatidylcholine for boosting immunity or treatment of bacterial infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110061316A KR101315483B1 (ko) 2011-06-23 2011-06-23 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
KR10-2011-0061316 2011-06-23

Publications (2)

Publication Number Publication Date
WO2012177075A2 WO2012177075A2 (ko) 2012-12-27
WO2012177075A3 true WO2012177075A3 (ko) 2013-03-28

Family

ID=47423102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004942 WO2012177075A2 (ko) 2011-06-23 2012-06-22 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물

Country Status (7)

Country Link
US (1) US9446061B2 (ko)
EP (1) EP2740479B1 (ko)
JP (2) JP5953372B2 (ko)
KR (1) KR101315483B1 (ko)
CN (1) CN103781483B (ko)
ES (1) ES2655193T3 (ko)
WO (1) WO2012177075A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
CN105764917B (zh) * 2013-09-26 2021-10-08 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
LT6177B (lt) 2014-10-10 2015-07-27 Uab "Biocentras" Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas
EP3684180A4 (en) * 2017-09-21 2021-07-07 The Scripps Research Institute NEW THERAPIES FOR THE TREATMENT AND PREVENTION OF CHRONIC RHINOSINUSITIS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920000322A (ko) * 1990-06-20 1992-01-29 아이젠브루크, 라피체 세팔로스포린 및 크산틴 유도체를 함유하는 약제학적 복합제 및 이의 용도
KR20040017613A (ko) * 2002-08-22 2004-02-27 주식회사 바이오시너젠 라이소포스파티딜콜린 또는 그 유사체를 포함하는 선천성면역 증강 조성물
KR20050034584A (ko) * 2001-10-05 2005-04-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물
KR20100120368A (ko) * 2009-05-06 2010-11-16 충남대학교산학협력단 도코사헥사에노일 리소포스파티딜콜린을 유효성분으로 함유하는 항염증 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
JP4320262B2 (ja) * 2002-03-25 2009-08-26 バイオシナジェン インコーポレイテッド Ｇ２ａ受容体に特異的な作用剤リガンドの新規な治療用途
CN101641095B (zh) * 2007-03-23 2012-10-31 巴斯利尔药物股份公司 用于治疗细菌感染的组合药物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920000322A (ko) * 1990-06-20 1992-01-29 아이젠브루크, 라피체 세팔로스포린 및 크산틴 유도체를 함유하는 약제학적 복합제 및 이의 용도
KR20050034584A (ko) * 2001-10-05 2005-04-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물
KR20040017613A (ko) * 2002-08-22 2004-02-27 주식회사 바이오시너젠 라이소포스파티딜콜린 또는 그 유사체를 포함하는 선천성면역 증강 조성물
KR20100120368A (ko) * 2009-05-06 2010-11-16 충남대학교산학협력단 도코사헥사에노일 리소포스파티딜콜린을 유효성분으로 함유하는 항염증 조성물

Also Published As

Publication number Publication date
JP2016147892A (ja) 2016-08-18
EP2740479A2 (en) 2014-06-11
JP6089130B2 (ja) 2017-03-01
KR20130000658A (ko) 2013-01-03
EP2740479A4 (en) 2015-03-11
WO2012177075A2 (ko) 2012-12-27
KR101315483B1 (ko) 2013-10-07
CN103781483B (zh) 2017-04-26
JP2014517064A (ja) 2014-07-17
US20140134210A1 (en) 2014-05-15
JP5953372B2 (ja) 2016-07-20
CN103781483A (zh) 2014-05-07
EP2740479B1 (en) 2017-10-25
US9446061B2 (en) 2016-09-20
ES2655193T3 (es) 2018-02-19

Similar Documents

Publication Publication Date Title
WO2012168431A3 (en) Polypeptides
WO2010092090A3 (en) Novel salts of sitagliptin
PH12015501609A1 (en) Phenicol antibacterials
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2013036783A3 (en) Methods for treating intrapulmonary infections
WO2012097185A3 (en) Omv vaccine against burkholderia infections
MX340985B (es) Compuestos de n-heteroarilo.
SG10201900541QA (en) Derivatives of xanthone compounds
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2012177075A3 (ko) 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
IN2014DN03010A (ko)
WO2012122451A3 (en) Polymorphs of maxacalcitol and process for the preparation of maxacalcitol
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
WO2011046905A3 (en) Pharmaceutical compositions
WO2014096300A3 (en) Antibacterial compounds
WO2014122671A3 (en) Solid oral compositions of saxagliptin
WO2013054364A3 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
WO2015065628A3 (en) Laquinimod combination therapy for treatment of multiple sclerosis
WO2010139411A3 (de) 17β-ALKYL-17α-OXY-ESTRATRIENE
WO2012071324A3 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12802590

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014516920

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012802590

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14128688

Country of ref document: US